Sanara MedTech Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

SMTI$32.10+1.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SANARA MEDTECH INC.
March 25, 2024	By:	/s/ Michael D. McNeil
		Michael D. McNeil
		Chief Financial Officer
		(Principal Financial Officer and duly authorized officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Zachary B. Fleming
Signature	Title	Date
/s/ Zachary B. Fleming	Chief Executive Officer (Principal Executive Officer)	March 25, 2024
/s/ Michael D. McNeil	Chief Financial Officer (Principal Financial and Accounting Officer)	March 25, 2024
Michael D. McNeil
/s/ Ronald T. Nixon	Chairman	March 25, 2024
Ronald T. Nixon
/s/ Robert DeSutter	Director	March 25, 2024
Robert DeSutter
/s/ Roszell Mack III	Director	March 25, 2024
Roszell Mack III
/s/ Eric D. Major	Director	March 25, 2024
Eric D. Major
/s/ Sara Ortwein	Director	March 25, 2024
Sara Ortwein
/s/ Ann Beal Salamone	Director	March 25, 2024
Ann Beal Salamone
/s/ James W. Stuckert	Director	March 25, 2024
James W. Stuckert
/s/ Eric D. Tanzberger	Director	March 25, 2024
Eric D. Tanzberger

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.